Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine

Biomarker Insights

Volumn 6, Issue , 2011, Pages 69-78

  Hintze, Jonathan P ^a   Tomatsu, Shunji ^a   Fujii, Tadashi ^b   Montaño, Adriana M ^a   Yamaguchi, Seiji ^c   Suzuki, Yasuyuki ^d   Fukushi, Masaru ^b   Ishimaru, Takeshi ^e   Orii, Tadao ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sapporo IDL   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

^d GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Seikagaku Biobusiness Corporation   (Japan)

^f GIFU UNIVERSITY   (Japan)

Author keywords

Biomarker; Clinical severity; Correlation; Monitor therapy; MPS IVA; Mucopolysaccharidosis IVA

Indexed keywords

KERATAN SULFATE;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MUCOPOLYSACCHARIDOSIS; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; URINE LEVEL;

IVA;

EID: 80053581510     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S7451     Document Type: Article

References (29)

1. Glössl J, Kresse H. Impaired degradation of keratan sulfate by Morquio A fibroblasts. Biochem J. 1982;203:335-8.
2. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165-74.
3. Montaño AM, Tomatsu S, Brusius S, Smith M, Orii T. Growth charts for patients affected with Morquio A disease. Am J Med Genet. 2008;146A:1286-95.
4. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment. Curr Pharm Biotechnol. 2011;12:931-45.
5. Thonar EJ, Pachman LM, Lenz ME, Hayford J, Lynch P, Kuettner KE. Age related changes in the concentration of serum keratan sulphate in children. J Clin Chem Clin Biochem. 1988;26:57-63.
6. Tomatsu S, Okamura K, Taketani T, Orii KO, Nishioka T, Gutierrez MA, et al. Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res. 2004;55:592-7.
7. Tomatsu S, Dieter T, Schwartz IV, Sarmient P, Giugliani R, Barrera LA, et al. Identification of a common mutation in mucopolysaccharidosis IVA: correlation among genotype, phenotype, and keratan sulfate. J Hum Genet. 2004;49:490-4.
8. Tomatsu S, Montaño AM, Oguma T, Dung VC, Oikawa H, de Carvalho TG, et al. Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis. 2010; DOI 10.1007/s10545-009-9013-x.
9. Hendriksz CJ, Vellodi A, Jones SA, Henkel C, Capponi M, Decker C. A phase 1/2, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and efficacy of BMN 110 in subjects with mucopolysaccharidosis IVA (Morquio syndrome). In Abstract book, 11th International Symposium on Mucopolysaccharide and Related Diseases, 23 June-26 June Adelaide; 2010.
10. Tomatsu S, Montaño AM, Molano ACS, Rowan D, Hintze JP, Carvalho CG, et al. Enzyme replacement therapy for lysosomal storage diseases. In Neurochemistry of Metabolic Diseases. Edited by Surendran S. Nova Science Publishers; 2011.
11. Alméciga-Dias CJ, Montaño AM, Tomatsu S, Barrera LA. Adeno-associated virus gene transfer in Morquio A disease-effect of promoters and sulfatasemodifying factor 1. FEBS J. 2010;277:3608-19.
12. Thonar EJ, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum. 1985;28:1367-76.
13. Thonar EJ, Manicourt DM, Williams J, Lenz ME, Sweet MB, Schnitzer TJ, et al. Circulating keratan sulfate: a marker of cartilage proteoglycan catabolism in osteoarthritis. J Rheumatol Suppl. 1991;27:24-6.
14. Poole AR, Witter J, Roberts N, Piccolo F, Brandt R, Paquin J, et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. Arthritis Rheum. 1990;33:790-9.
15. Sweet MB, Coelho A, Schnitzler CM, Schnitzer TJ, Lenz ME, Jakim I, et al. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum. 1988;31:648-52.
16. Tomatsu S, Okamura K, Maeda H, Taketani T, Castrillon SV, Gutierrez MA, et al. Keratan sulfate levels in mucopolysaccharidosis and mucolipidoses. J Inherit Metab Dis. 2005;28:187-202.
17. Humbel R. Identification and quantitation of keratan sulfate in urine. Clin Chim Acta. 1974;52:173-7.
18. Melrose J, Ghosh P. The quantitative discrimination of corneal type I, but not skeletal type II, keratan sulfate in glycosaminoglycan mixtures by using a combination of dimethylmethylene blue and endo-beta-D-galactosidase digestion. Anal Biochem. 1988;170:293-300.
19. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986;883:173-7.
20. Oguma T, Tomatsu S, Okazaki O. Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr. 2007;21:356-62.
21. Johnston I. I'll give you a definite maybe: An introductory handbook on probability, statistics, and excel, 2000; [https://records.viu.ca/~johnstoi/maybe/title.htm].
22. Roughley PJ. The structure and function of cartilage proteoglycans. Eur Cells Mater. 2006;12:92-101.
23. Brown GM, Huckerby TN, Bayliss MT, Nieduszynski IA. Human aggrecan keratan sulfate undergoes structural changes during adolescent development. J Biol Chem. 1998;273:26408-14.
24. Funderburgh JL. Keratan sulfate: structure, biosynthesis, and function. Glycobiology. 2000;10:951-8.
25. Ohashi A, Montaño AM, Colón JE, Oguma T, Luisiri A, Tomatsu S. Sacral dimple: Incidental findings from newborn evaluation. Acta Paediatr. 2009;98:768-9.
26. Tomatsu S, Montaño AM, Ohashi A, Gutierrez MA, Oikawa H, Oguma T, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet. 2008;17:815-24.
27. Tomatsu S, Montaño AM, Dung VC, Ohashi A, Oikawa H, Oguma T, et al. Enhancement of drug delivery: enzyme replacement therapy for murine Morquio A syndrome. Mol Ther. 2010;18:1094-102.
28. Mehmet H, Scudder P, Tang PW, Hounsell EF, Caterson B, Feizi T. The antigenic determinants recognized by three monoclonal antibodies to keratan sulphate involve sulphated hepta-or larger oligosaccharides of the poly (N-acetyllactosamine) series. Eur J Biochem. 1986;157:385-91.
29. Caterson B, Christner JE, Baker JR. Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulfate. Monoclonal antibodies to cartilage proteoglycan. J Biol Chem. 1983;258:8848-54.